[HTML][HTML] Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer
C Coutzac, JM Jouniaux, A Paci, J Schmidt… - Nature …, 2020 - nature.com
Gut microbiota composition influences the clinical benefit of immune checkpoints in patients
with advanced cancer but mechanisms underlying this relationship remain unclear …
with advanced cancer but mechanisms underlying this relationship remain unclear …
[HTML][HTML] Integrating circulating biomarkers in the immune checkpoint inhibitor treatment in lung cancer
B Duchemann, J Remon, M Naigeon, L Mezquita… - Cancers, 2020 - mdpi.com
Simple Summary Immune checkpoint inhibitors (ICI) are now a cornerstone of treatment for
non-small cell lung cancer (NSCLC). Despite reporting tremendous results for some …
non-small cell lung cancer (NSCLC). Despite reporting tremendous results for some …
Circulating T-cell immunosenescence in patients with advanced non–small cell lung cancer treated with single-agent PD-1/PD-L1 inhibitors or platinum-based …
Abstract Purpose: CD28, CD57, and KLRG1 have been previously identified as markers of T-
cell immunosenescence. The impact of immunosenescence on anti-PD (L)-1 (ICI) or …
cell immunosenescence. The impact of immunosenescence on anti-PD (L)-1 (ICI) or …
[HTML][HTML] Current and future biomarkers for outcomes with immunotherapy in non-small cell lung cancer
B Duchemann, J Remon, M Naigeon… - Translational Lung …, 2021 - ncbi.nlm.nih.gov
Immune checkpoint inhibitors (ICI) have been validated as an effective new treatment
strategy in several tumoral types including lung cancer. This remarkable shift in the …
strategy in several tumoral types including lung cancer. This remarkable shift in the …
Human virome profiling identified CMV as the major viral driver of a high accumulation of senescent CD8+ T cells in patients with advanced NSCLC
M Naigeon, M Roulleaux Dugage, FX Danlos… - Science …, 2023 - science.org
Circulating senescent CD8+ T (T8sen) cells are characterized by a lack of proliferative
capacities but retain cytotoxic activity and have been associated to resistance to …
capacities but retain cytotoxic activity and have been associated to resistance to …
[HTML][HTML] CD8+ PD-1+ to CD4+ PD-1+ ratio (PERLS) is associated with prognosis of patients with advanced NSCLC treated with PD-(L) 1 blockers
B Duchemann, M Naigeon, E Auclin… - … for Immunotherapy of …, 2022 - ncbi.nlm.nih.gov
Background Programmed cell death protein-1 (PD-1) expression has been associated with
activation and exhaustion of both the CD4 and CD8 populations in advanced non-small cell …
activation and exhaustion of both the CD4 and CD8 populations in advanced non-small cell …
[HTML][HTML] Overcoming resistance to αPD-1 of MMR-deficient tumors with high tumor-induced neutrophils levels by combination of αCTLA-4 and αPD-1 blockers
L Nebot-Bral, A Hollebecque… - … for Immunotherapy of …, 2022 - ncbi.nlm.nih.gov
Background Clinical studies have highlighted the efficacy of anti-programmed death 1 (αPD-
1) monoclonal antibodies in patients with DNA mismatch repair-deficient (MMRD) tumors …
1) monoclonal antibodies in patients with DNA mismatch repair-deficient (MMRD) tumors …
[HTML][HTML] B cells and the coordination of immune checkpoint inhibitor response in patients with solid tumors
R Flippot, M Teixeira, M Rey-Cardenas… - … for Immunotherapy of …, 2024 - ncbi.nlm.nih.gov
Immunotherapy profoundly changed the landscape of cancer therapy by providing long-
lasting responses in subsets of patients and is now the standard of care in several solid …
lasting responses in subsets of patients and is now the standard of care in several solid …